Apimeds Pharmaceuticals US, Inc.
NYSE · CIK 0001894525 · Fiscal year end 1231
Latest reported period: Latest published period
Operating Income
$-12.2M
Net Income
$-35.1M
Eps Basic
-2.26
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-12.2M | - | - |
| Net Income | $-35.1M | - | - |
| Eps Basic | -2.26 | - | - |
| Eps Diluted | -2.26 | - | - |
| Cash And Equivalents | $979,534 | - | - |
| Total Assets | $141.2M | - | - |
| Total Liabilities | $14.7M | - | - |
| Shareholders Equity | $126.5M | - | - |
| Operating Cash Flow | $-2.1M | - | - |
| Capital Expenditures | $9,394 | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | Apimeds Pharmaceuticals US, Inc. | 2026-05-26 | 0001213900-26-061013 |
| 10-K | Apimeds Pharmaceuticals US, Inc. | 2026-05-04 | 0001213900-26-051139 |
| 10-Q | Apimeds Pharmaceuticals US, Inc. | 2025-11-12 | 0001213900-25-109280 |
| 10-Q | Apimeds Pharmaceuticals US, Inc. | 2025-08-19 | 0001213900-25-078507 |